언어 선택

VEGF-B

VEGF-B 분자 정보

영어 이름	Vascular endothelial growth factor B	시판 약물 수	1
임상 약물 수	4	표적 별명	VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
최고 연구 개발 단계	Approved

영어 이름	Vascular endothelial growth factor B
표적 별명	VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
시판 약물 수	1
임상 약물 수	4
최고 연구 개발 단계	Approved

VEGF-B 제품 목록

속성
Protein (1)
제품 라이브러리
온라인 (1)
종
Human (1)
태그
His Tag (1)
마커
Unconjugated (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
VE6-H5225	Human	HEK293	Human VEGF-B Protein, His Tag

총 수량1

VEGF-B분자 배경

Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.

VEGF-B분자 별명

VRF,VEGFL,VEGFB,VEGF-B

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
4D-150	4D-150	Phase 3 Clinical	4d Molecular Therapeutics Inc	Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration	상세
Reflocibart	2H-10; CSL-346	Phase 2 Clinical	Csl Ltd	Diabetic Nephropathies	상세
PB-101	PB-101	Phase 1 Clinical	Panolos Bioscience Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms	상세
EB-105	EB-105	Phase 1 Clinical	Eluminex Biosciences (Suzhou) Ltd	Diabetic macular oedema; Diabetic Retinopathy	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Ziv-aflibercept	AVE-0005; BAY-865321	Approved	Regeneron Pharmaceuticals Inc, Sanofi	Zaltrap	United States	Colorectal Neoplasms	Sanofi-Aventis U.S. Llc	2012-08-03	Adenocarcinoma, Follicular; Ascites; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Gliosarcoma; Leiomyosarcoma; Leukemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Chronic; Lung Diseases; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 1; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Retinal Vein Occlusion; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid	상세